These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2912020)

  • 1. Phase II trial of N-methylformamide in advanced renal cancer.
    Abrams JS; Tait N; Silva H; Eisenberger M; Van Echo DA; Olver IN; Aisner J
    Am J Clin Oncol; 1989 Feb; 12(1):41-2. PubMed ID: 2912020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of N-methylformamide for advanced renal cell carcinoma.
    Sternberg CN; Yagoda A; Scher HI; Hollander P
    Cancer Treat Rep; 1986 May; 70(5):681-2. PubMed ID: 3708620
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
    Rowinsky EK; Grochow LB; Hantel A; Ettinger DS; Vito BL; Donehower RC
    Invest New Drugs; 1989 Nov; 7(4):317-25. PubMed ID: 2599802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial.
    Rajdev L; Yu ZF; Wadler S; Weller E; Kahn SB; Tormey D; Skeel R; Wiernik PH
    Invest New Drugs; 2001; 19(3):233-7. PubMed ID: 11561680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of N-methylformamide (NMF, NSC 3051).
    O'Dwyer PJ; Donehower M; Sigman LM; Fortner CL; Aisner J; Van Echo DA
    J Clin Oncol; 1985 Jun; 3(6):853-7. PubMed ID: 4009219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of N-methylformamide in advanced head and neck cancer.
    Vogel WC; Forastiere AA; Natale RB; Takasugi BJ; Schnur G
    Invest New Drugs; 1987; 5(2):203-6. PubMed ID: 3654153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of N-methylformamide in patients with metastatic melanoma.
    Eton O; Bajorin DF; Casper ES; Houghton AN
    Invest New Drugs; 1991 Feb; 9(1):97-100. PubMed ID: 2026491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-methylformamide-induced hypophosphatemia.
    Sternberg CN; Yagoda A
    Cancer Treat Rep; 1985 Mar; 69(3):343-4. PubMed ID: 3978663
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase I trial of N-methylformamide.
    McVie JG; ten Bokkel Huinink WW; Simonetti G; Dubbelman R
    Cancer Treat Rep; 1984 Apr; 68(4):607-10. PubMed ID: 6325001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.
    Rowinsky EK; Noe DA; Orr DW; Grochow LB; Ettinger DS; Donehower RC
    J Natl Cancer Inst; 1988 Jul; 80(9):671-8. PubMed ID: 3373556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of N-methylformamide in patients with advanced colorectal carcinoma.
    Tauer K; Kemeny N; Cheng E; Hollander P; Geller N
    Cancer Treat Rep; 1986 Jun; 70(6):813-4. PubMed ID: 3524831
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase I study of N-methylformamide in patients with advanced cancer.
    Ettinger DS; Orr DW; Rice AP; Donehower RC
    Cancer Treat Rep; 1985 May; 69(5):489-93. PubMed ID: 4005871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Eisenhauer EA; Weinerman BH; Kerr I; Quirt I
    Cancer Treat Rep; 1986 Jul; 70(7):881-3. PubMed ID: 3719579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
    Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
    Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.
    Higano CS; Goodman P; Craig JB; Kish JA; Rivkin SE; Wolf M; Crawford ED
    Invest New Drugs; 1991 Nov; 9(4):361-3. PubMed ID: 1804814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
    Shevrin DH; Lad TE; Kilton LJ; Cobleigh MA; Blough RR; Weidner LL; Vogelzang NJ
    Invest New Drugs; 1989 Jul; 7(2-3):251-3. PubMed ID: 2477345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
    Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of N-methylformamide in patients with advanced colorectal cancer.
    Tchekmedyian NS; Kaplan RS; Eisenberger M; Abrams J; Van Echo D
    Cancer Treat Rep; 1987 May; 71(5):541-2. PubMed ID: 3567980
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II study on oral N-methylformamide in metastatic colorectal cancer.
    Planting AS; Klijn JG; Verweij J; Stoter G
    Cancer Treat Rep; 1987 Dec; 71(12):1293-4. PubMed ID: 3690540
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.